Debolina Ganguly retweeted
Metastasis kills most cancer patients and grows from invisible seeds. How do these seeds escape from attack by immune cells? These seeds harness stress hormones!š¤Æ
ā¦thanks to ā¦@nyscfā© ā¦@parkericiā© for their support. Today at ā¦@Natureā© nature.com/articles/s41586-0ā¦
Debolina Ganguly retweeted
Where do cancers start? In the liver, not all cells are the same. The liver is divided into 3 āzones,ā and each specializes in different metabolic tasks. We show in @Science that where a mutation occurs in a liver lobule can determine a cellās fate. science.org/doi/10.1126/scie⦠(1/9)
Debolina Ganguly retweeted
BREAKING NEWS
The 2025 #NobelPrize in Physiology or Medicine has been awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi āfor their discoveries concerning peripheral immune tolerance.ā
Debolina Ganguly retweeted
Stellar postdoc ā¦@DebolinaGangulyā© and I wrote this spotlight in for a super cool paper on the systemic effects of metatasis in breast cancer. The organ of metastatic disease has a BIG impact! Highly recommended paper in ā¦@Cancer_Cellā© secure-web.cisco.com/1be_LDSā¦
Debolina Ganguly retweeted
1/ šØ Hot off the press in @NatImmunol: CD4āŗ T cells can license Kupffer cells to rescue dysfunctional CD8āŗ T cells in the liver. Hepatitis B virus (HBV) infection is just the proving groundāthis is a paradigm shift in tissue immunity. nature.com/articles/s41590-0⦠š§µ(1/11)
2/ Chronic HBV infection was the perfect stress test: intrahepatic CD8āŗāÆT cells are primed yet quickly stall. How to reignite them has been a major interest of our lab. (2/11)
3/ Preāactivated helper CD4āŗāÆT cells solve the puzzle. They skip lymph nodes and head straight to the liver, where they form intimate triads with Kupffer cells (KCs), the resident macrophages patrolling sinusoids. (3/11)
4/ Through CD40LāCD40 contact, those helpers reāprogram KCsāturning tolerant scavengers into potent APCālike cytokine factories. Itās onāsite immune engineering, not remote coaching. (4/11)
5/ Licensed KCs release a twoāpart cocktail:
⢠ILā12 expands the helper pool
⢠ILā27 wakes up dysfunctional CD8āŗāÆT cells, restoring effector molecules and metabolic vigor. (5/11)
6/ Dendritic cells? Dispensable. Secondary lymphoid organs? Surgically removed or pharmacologically blockedāhelp still flows. Immunity can be fabricated in situright inside the parenchyma. (6/11)
7/ Remove KCs and the circuit collapses; block CD40L or ILā27 and CD8āŗāÆT cells relapse into lethargy. The essential loop is:
CD4āÆT cell ā KC ā ILā27 āCD8āÆT cell. (7/11)
8/ ILā27 isnāt just necessaryāitās sufficient. Recombinant ILā27 revived antiviral CD8āŗāÆactivity in mice and superācharged HBVāspecific T cells from patients. (8/11)
9/ Why care beyond HBV? Tapping a CD4āILā27 axis could be a universal key to reāarming liverāresident CD8āŗāÆT cells against infections and cancer (9/11)
10/ The work reframes āCD4 helpā: not a lymphānode pep talk but an onāsite renovation that overrides local tolerance. Therapeutics that mimic KC licensing could deliver potency where itās needed and spare the rest of the body. (10/11)
11/ Kudos to Valentina Venzin, Cristian Beccaria, all members of the @IannaconeLab & collaborators for charting this intrahepatic circuit. Expect Kupfferācell licensing and ILā27 to enter conversations on cancer immunotherapy, vaccines and beyond. Thoughts welcome! š
@ImmunoPodcast @profvrr @ERC_Research @EMBO @EMBO_YIP @ArmeniseHarvard
@AIRC_it @MyUniSR @SanRaffaeleMI
(11/11)
Debolina Ganguly retweeted
#UTSW biochemist Zhijian "James" Chen, Ph.D., wins the Albert Lasker Basic Medical Research Award, sometimes called āAmericaās Nobel,ā for his discovery of the cGAS enzyme, which senses invading pathogens and triggers immune response. bit.ly/3MQjHIr @LaskerFDN
Debolina Ganguly retweeted
Debolina Ganguly, PhD (@debog93), a 2024 Parker Scholar at @DanaFarber, studies how metastatic stem cells promote systemic tolerance to tumor antigens & suppress responses to immunotherapy, advancing understanding of patient response. Hear more about PICIās support of her work.
Debolina Ganguly retweeted
So proud of @debog93 for receiving this prestigious fellowship from @parkerici to discover how to make breast cancer responsive to immunotherapy. World, get ready, a new super star is rising!
PICI is thrilled to award over $1 million in total to our 2024 class of Early Career Researcher recipients. These bold investigators are propelling #immunotherapy w/ pioneering research that could lead to breakthrough discoveries. Meet the 2024 awardees: linkedin.com/feed/update/urnā¦
Debolina Ganguly retweeted
With Pravat starting his lab @IISER and Kangsan joining @AstraZeneca as Senior scientist, we are looking for aspiring #postdocs to join us. Please reach out if you are interested in studying and developing strategies to prevent #metastasis !! Please RT
shorturl.at/isQY6 1/2
Debolina Ganguly retweeted
Best Bday gift ever! Happy bday to me!𤩠collaboration with gut stem cell super expert ā¦@ohyilmazā© to find how immunogenic Lgr5 cells can grow into tumors and evade immune surveillance. Team work makes the dream work (and the fun work!) nature.com/articles/s41586-0ā¦
Debolina Ganguly retweeted
open access link to our paper. We prove: 1. immune cells can prevent cancer, and 2. Mutated cells must turn immune silent to grow cancer, here with a fetal reprogramming. With gut stem cell expert ā¦@ohyilmazā© and me as the immune evasion expert secure-web.cisco.com/1BU72ZRā¦
Debolina Ganguly retweeted
āTen years ago I was kicked out and forced to retire.ā
Our new medicine laureate Katalin Karikó (@kkariko) told us how much it means to be awarded the Nobel Prize after a scientific career that has been full of challenges.
Ten years ago, Karikó was still doing all her experiments by hand but today she has been awarded the medicine prize for her research on mRNA, which led to the development of COVID-19 vaccines.
Listen now:
Debolina Ganguly retweeted
Replying to @UTSWCancerBio
Debolina Ganguly retweeted
Recruiting postdocs interested in immune evasion and #breastcancer . Experience in cloning/cell engineering and in vivo mouse work are a plus! See the type of work we doš cell.com/cell/pdf/S0092-8674ā¦
Debolina Ganguly retweeted
A great joint journal club discussing complex issue in #breastcancer #immunology with powerhouse labs @SandraMcAllist4 @JudithAgudo1 @vangalenlab @EMittendorfMD. Only screenshot I got...we are deep in thought! @DFCI_BreastOnc @BrighamSurgery
Debolina Ganguly retweeted
Pleiotrophin drives a prometastatic immune niche in #BreastCancer, say Debolina Ganguly @debog93, Rolf Brekken @brekkenlab et al @utswcancer @UTSWNews: https://nitter.cf/t.co/kZIscBCcEe
@gilbertzmurimwa @FaValdesMora @dgallegoortega
#TumorImmunology #metastasis
Debolina Ganguly retweeted
.@debog93 @brekkenlab et al @utswcancer find that metastatic #BreastCancer cells thrive in secondary organs by producing pleiotrophin & activating the NF-ĪŗB pathway, leading to increased cytokine production, neutrophil recruitment, and T cell dysfunction. https://nitter.cf/t.co/kZIscBCcEe
Debolina Ganguly retweeted
My fellows are getting jobs. Great, except my lab is shrinking! We will be looking for postdocs to join us in studying how the tumor immune microenvironment (incl. neutrophils) & systemic changes (incl. those caused by stress) control metastasis. Email me: [email protected]
Debolina Ganguly retweeted
Here's one of a number of positions available in our lab: nature.com/naturecareers/job⦠Get in touch if you're interested in solving new mysteries about drug resistance, tumor dormancy, or anything else!


























